Значение циркулирующих опухолевых маркеров при раке легкого в клинической практике
https://doi.org/10.18027/2224-5057-2020-10-2-2
Аннотация
Ключевые слова
Об авторе
И. В. РыковРоссия
Иван В. Рыков, к. м. н., заведующий отделением онкологии
Санкт-Петербург
Список литературы
1. Ardizzoni, A. C. (2006). Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer , 107: 2842 2849.
2. Burghuber OC, W. B. (1990). Serum neuron specific enolase is a useful tumor marker for small cell lung cancer. Cancer. , 1386–1390.
3. Cui Haoa, G. L. (2019). Progress in Molecular Biology and Translational Science. Serum CEA levels in 49 different types of cancer and noncancer diseases. Elsevier.
4. Dal Bello MG, F. R. (2019). The role of CEA, CYFRA 21 1 and NSE in monitoring tumor response to Nivolumab in advanced non small cell lung cancer (NSCLC) patients. J Transl Med. , 17(1):74.
5. Dong A, Z. J. ( 2019). Diagnostic value of ProGRP for small cell lung cancer in different stages. . J Thorac Dis. , 11(4):1182 1189.
6. Edith Borcoman, M. A. (2018). ASCO EDUCATIONAL BOOK. American Society of Clinical Oncology.
7. H.J. Schmoll, L. V. (2015). ESMO Handbook of Cancer Diagnosis and Treatment Evaluation.
8. Holdenrieder S, W. B. (2017). Carcinoembryonic antigen and cytokeratin 19 fragments for assessment of therapy response in non small cell lung cancer: a systematic review and meta analysis. Br J Cancer. , 116(8):1037–1045.
9. J. L. Patel, J. A. (2008). Value of CYFRA 21 1,carcinoembryonic antigen, and squamous cell carcinoma antigen as tumor markers in non small cell lung cancer patients. Journal of Clinical Oncology , 19042 19042.
10. Liu L, T. J. (2017). The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer. Biomed Res Int. , 017:2013989.
11. Liu X, Z. W. (2017). The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first line platinum based chemotherapy. Medicine (Baltimore). , 96(46):e8258.
12. Okamura K, T. K. (2013). Diagnostic value of CEA and CYFRA 21 1 tumor markers in primary lung cancer. Lung Cancer , 80(1):45–49.
13. Ono A, N. T. (2012). Correlations between serial pro gastrin releasing peptide and neuron specific enolase levels, and the radiological response to treatment and survival of patients with small cell lung cancer. Lung Cancer. , 439–444.
14. Shirasu H, O. A. (2018). CYFRA 21 1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. Tumour Biol. , 40(2).
15. Wieskopf B, D. C. (1995). CYFRA 21 1 as a biologic marker of non small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest. , 108(1):163–169.
16. Wójcik E, K. J. K. (2008). ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res. , 28(5B):3027–3033.
17. Yonemori K, S. M. (2005). Pro gastrin releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation. Cancer. , 104(4):811–816.
18. Yoshimura A, U. J. (2019). Carcinoembryonic antigen and CYFRA 21 1 responses as prognostic factors in advanced non small cell lung cancer. Translational lung cancer research vol. 8 , 227–234.
Рецензия
Для цитирования:
Рыков И.В. Значение циркулирующих опухолевых маркеров при раке легкого в клинической практике. Злокачественные опухоли. 2020;10(2):31-35. https://doi.org/10.18027/2224-5057-2020-10-2-2
For citation:
Rykov I.V. The importance of circulating tumor markers in lung cancer in clinical practice. Malignant tumours. 2020;10(2):31-35. (In Russ.) https://doi.org/10.18027/2224-5057-2020-10-2-2